Last updated on August 2018

Study Maintenance Regorafenib vs Placebo no Progression Patients After I Line Chemotherapy Metastatic Gastric Cancer


Brief description of study

Randomized, double-blind, placebo-controlled, multicenter Phase-II study.

Approximately 120 subjects with CR/PR/SD after platinum compounds and fluoropyrimidines based regimens: up to 6 cycles of cisplatin and 5-fluorouracil or capecitabine, up to 12 cycles of FOLFOX, up to 8 cycles of XELOX, will be randomly assigned (1:1 ratio) to one of the following treatment groups:

Arm A: Placebo 4 tablets once daily on day 1-21, every 4 weeks, until intolerance or progression disease Arm B: Regorafenib 160 mg, 4 tablets once daily on days 1-21, every 4 weeks, until intolerance or progression disease Primary Variable: PFS1

Clinical Study Identifier: NCT03627728

Find a site near you

Start Over